Page last updated: 2024-08-21

pyrazines and Cancer of Prostate

pyrazines has been researched along with Cancer of Prostate in 70 studies

Research

Studies (70)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (1.43)	18.2507
2000's	36 (51.43)	29.6817
2010's	31 (44.29)	24.3611
2020's	2 (2.86)	2.80

Authors

Authors	Studies
Ji, Z; Li, H; Yan, W; Yu, X; Zhou, Y; Zhou, Z	1
Iwai, F; Kato-Ogura, A; Onaka, T; Otsuka, Y; Yonezawa, A	1
Ji, Z; Li, H; Xiao, Y; Yan, W; Zhou, Y; Zhou, Z	1
Bisonette, RR; Fultz, KE; Gamez, JC; Harris, R; Hickman, M; Khambatta, G; Lee, BG; Leisten, J; Mortensen, DS; Narla, RK; Parnes, JS; Peng, S; Perrin-Ninkovic, SM; Sankar, S; Sapienza, J; Shevlin, G; Whitefield, B	1
Andersen, KF; Divilov, V; Koziorowski, J; Lewis, JS; Pillarsetty, N	1
Chang, TP; Gatla, HR; Manna, S; Phyo, SA; Ramaswami, S; Sanacora, S; Singha, B; Vancurova, I	1
Cho, NH; Choi, HK; Chun, YJ; Im, HJ; Kim, D; Kwon, Y; Park, N; Park, YS; Shin, S; Sung, CH; Ye, DJ	1
Coelho, MA; Coelho, SC; Juzenas, P; Pereira, MC; Rocha, S	1
Gao, ZY; Hu, W; Wang, W	1
Gurocak, S; Kiliccioglu, I; Konac, E; Varol, N; Yucel Bilen, C	1
Ding, Y; Guo, S; Li, X; Shan, B; Shi, P; Shu, X; Wang, J; Wang, Z; Xing, L; Zhang, Y	1
Chauhan, P; Hart, KM; Liu, CG; Liu, R; Liu, X; Mao, X; Wang, L; Wei, S; Yang, WH; Yi, B; Zhang, W	1
Guo, W; Han, J; He, X; Huang, H; Li, X; Li, Y; Liu, X; Song, J; Wang, S; Xing, W; Xu, X; Zhao, R; Zhu, M	1
Apuy, J; Bahmanyar, S; Bisonette, RR; Canan, SS; Cathers, BE; Correa, M; Elsner, J; Fultz, KE; Gamez, JC; Harris, R; Hickman, M; Khambatta, G; Lee, BG; Leisten, J; Moghaddam, MF; Mortensen, DS; Narla, RK; Packard, G; Papa, P; Parnes, JS; Peng, SX; Perrin-Ninkovic, SM; Raymon, HK; Richardson, SJ; Riggs, JR; Sankar, S; Sapienza, J; Shevlin, G; Tehrani, L; Whitefield, B; Worland, P; Zhao, J	1
Balk, SP; Cai, C; Chen, S; Gerrin, SJ; He, HH; He, L; Ma, F; Sowalsky, AG; Tanenbaum, BA; Wang, H; Ye, H; Yuan, X	1
Cao, W; Namiki, K; Porvasnik, S; Rosser, CJ; Sakai, Y; Shiverick, KT; Urbanek, C	1
Bertoni, F; Capri, G; Catapano, CV; Cresta, S; Gallerani, E; Gianni, L; Maccioni, E; Maur, M; Passalacqua, D; Rinaldi, A; Sessa, C; Tosi, D; Viganò, L	1
Ayala, G; Ding, Y; Frolov, A; Harper, JW; Hayes, TG; Ittmann, MM; Kadmon, D; Li, R; Lynch, RG; MacDonnell, V; Miles, BJ; Mims, MP; Thompson, TC; Tsai, MJ; Wheeler, TM; Yan, J	1
Christian, PA; Schwarze, SR; Thorpe, JA	2
Voelkel-Johnson, C	1
Avcu, F; Aydur, E; Baran, Y; Basal, S; Beyzadeoglu, M; Dirican, B; Goktas, S; Pekel, A; Ural, AU; Yazici, S	1
Baritaki, S; Berenson, J; Bonavida, B; Palladino, M; Yeung, K	1
Dunner, K; McConkey, DJ; Zhu, K	1
Ikeda, D; Inoue, H; Kato, T; Kawada, M; Masuda, T; Ohba, S; Someno, T	1
Belmonte, C; Morenilla-Palao, C; Valero, M; Viana, F	1
Fujisawa, M; Miyake, H; Sakai, I; Terakawa, T	1
Breen, M; Chen, CS; Keller, ET; Kisseberth, WC; Lanigan, LG; Martin, CK; McCauley, LK; Murahari, S; Nadella, MV; Rosol, TJ; Shu, ST; Simmons, JK; Thudi, NK; Van Bokhoven, A; Werbeck, JL; Williams, C	1
Bannerman, B; Berger, A; Bolen, J; Claiborne, C; Dick, L; Fleming, P; Hales, P; Jones, M; Kupperman, E; Manfredi, M; Monbaliu, J; Tsu, C; Xu, L; Yu, J	1
Dou, QP; Frezza, M; Yang, H	1
Bearden, J; Butler, W; Chen, CS; Garrett-Mayer, E; Golshayan, A; Kraft, AS; Lilly, M; Wahlquist, AE	1
Befani, CD; Bonanou, S; Hatzidaki, E; Liakos, P; Papandreou, CN; Patrikidou, A; Simos, G; Vlachostergios, PJ	1
Della Donna, L; Lagadec, C; Pajonk, F	1
Bhalla, P; Budunova, I; Iwadate, K; Karseladze, A; Ugolkov, A; Yang, X; Yemelyanov, A	1
Befani, CD; Daliani, DD; Hatzidaki, E; Liakos, P; Moutzouris, G; Papandreou, CN; Patrikidou, A; Tsapakidis, K; Vlachostergios, PJ; Voutsadakis, IA	1
Al-Husein, B; Al-Shabrawey, M; Bollag, WB; Choudhary, V; Davis, M; Dong, Z; El Gaish, M; Kaddour-Djebbar, I; Kumar, MV; Lakshmikanthan, V; Shirley, R; Zhong, R	1
Stockler, MR; Wilcken, NR	1
Bauer, F; Codreanu, I; Dasanu, CA; Padmanabhan, P; Rampurwala, M	1
Cui, HX; Hu, W; Jiang, YH; Wang, Y; Yue, D; Zheng, RR	1
Asano, T; Ito, K; Sato, A	1
Adams, J; An, J; Belldegrun, A; Fisher, M; Rettig, MB; Sun, YP	1
Logothetis, C; McConkey, DJ; Papandreou, C; Pettaway, C; Song, R; Williams, S	1
McConkey, DJ; Williams, SA	1
Ikezoe, T; Koeffler, HP; Saito, T; Taguchi, H; Yang, Y	1
Adams, J; Daliani, DD; Dieringer, P; Elliott, P; Esseltine, D; Kim, J; Logothetis, CJ; Madden, T; Millikan, RE; Nix, D; Pagliaro, L; Papandreou, CN; Perez, C; Petrusich, A; Pien, CS; Tu, SM; Wang, X; Yang, H	1
Boone, CW; Christov, KT; Kelloff, GJ; Lantvit, DD; Lubet, RA; Moon, RC; Pezzuto, JM; Steele, VE	1
Logothetis, CJ; Papandreou, CN	1
Gudegast, C; Stöckle, M; Tahmatzopoulos, A; Unteregger, G; Wullich, B; Zwergel, T; Zwergel, U	1
Dreicer, R; Price, N	1
Adams, J; Coultas, L; Johnson, T; Kraft, AS; Nikrad, M; Puthalalath, H	1
Bold, RJ; Fahy, BN; Mortenson, MM; Schlieman, MG; Virudachalam, S	1
Brodie, AM; Chopra, P; Farquhar, R; Gediya, LK; Guo, Z; Handratta, VD; Kataria, R; Newman, D; Njar, VC; Qiu, Y; Vasaitis, TS	1
Nelson, JB; Smith, MR	1
Dinney, CP; Lashinger, LM; McConkey, DJ; Shrader, M; Williams, SA; Zhu, K	1
Alexandre, J	1
Gamradt, SC; Gates, JJ; Lieberman, JR; Whang, PG	1
Jaehde, U; Scheulen, ME; Simons, S	1
Davis, M; Donovan, JL; Hamdy, FC; Lane, JA; Metcalfe, C; Mills, N; Neal, DE; Peters, TJ; Ronsmans, C; Sterne, JA	1
Esseltine, D; MacGregor-Cortelli, B; Muzzy, J; O'Connor, OA; Schenkein, D; Scher, H; Slovin, S; Stubblefield, MD; Wright, J	1
Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, A; Takayama, H	2
Canfield, SE; McConkey, DJ; Williams, SA; Zhu, K	1
Birle, DC; Hedley, DW	1
Agus, D; Dreicer, R; Petrylak, D; Roth, B; Webb, I	1
Barton, J; Gould, B; Greco, FA; Hainsworth, JD; Meluch, AA; Meng, C; Simons, L; Spigel, DR	1
Banu, E; Beuzeboc, P; Guyader, C; Medioni, J; Oudard, S; Scotte, F	1
Eicher, C; Heller, G; Kelly, WK; Morris, MJ; Ryan, C; Scher, HI; Slovin, S	1
Doroshow, J; Edelman, MJ; Grennan, T; Lauder, J; Meyers, FJ	1
Ansari, RH; Kugler, JW; Richards, JM; Ryan, CW; Shulman, KL; Sosman, JA; Vogelzang, NJ; Vokes, EE	1
Adams, J; Elliott, P; Frankel, A; Kerbel, RS; Man, S	1

Reviews

6 review(s) available for pyrazines and Cancer of Prostate

Article	Year
Bortezomib as a potential treatment for prostate cancer. Cancer research, 2004, Aug-01, Volume: 64, Issue:15 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Humans; Male; Multienzyme Complexes; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines	2004
[Proteasome inhibitors: induction of apoptosis as new therapeutic option in prostate cancer]. Aktuelle Urologie, 2004, Volume: 35, Issue:6 Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Male; Mice; Mice, Nude; Neoplasms, Experimental; Prostate-Specific Antigen; Prostatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha	2004
Future therapies in hormone-refractory prostate cancer. Urology, 2005, Volume: 65, Issue:5 Suppl Topics: Antibodies, Monoclonal; Atrasentan; Boronic Acids; Bortezomib; Diphosphonates; DNA, Antisense; Forecasting; Humans; Immunotherapy; Male; Prostatic Neoplasms; Pyrazines; Pyrrolidines; Receptors, Growth Factor; Thalidomide	2005
[Bortezomib]. Deutsche medizinische Wochenschrift (1946), 2006, Feb-03, Volume: 131, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Humans; Kidney Neoplasms; Leukemia; Lymphoma, Non-Hodgkin; Male; Multiple Myeloma; Prostatic Neoplasms; Protease Inhibitors; Pyrazines	2006
[New targeted therapies in hormone-refractory prostate cancer]. Bulletin du cancer, 2007, Volume: 94, Issue:7 Suppl Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Calcitriol; Cancer Vaccines; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Endothelin-1; Epothilones; Humans; Male; Oligonucleotides, Antisense; Organoplatinum Compounds; Prostatic Neoplasms; Protease Inhibitors; Protein Kinase Inhibitors; Pyrazines; Taxoids	2007
[Molecular-targeted therapy for prostate cancer]. Hinyokika kiyo. Acta urologica Japonica, 2008, Volume: 54, Issue:1 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Male; Neoplasms, Hormone-Dependent; NF-kappa B; Prostatic Neoplasms; Pyrazines; Thalidomide	2008

Trials

10 trial(s) available for pyrazines and Cancer of Prostate

Article	Year
Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:13 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Pyrazines; Treatment Outcome	2008
Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Nov-15, Volume: 14, Issue:22 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Flow Cytometry; Histone Acetyltransferases; Humans; Immunohistochemistry; Male; Middle Aged; Neoadjuvant Therapy; NF-kappa B; Nuclear Receptor Coactivator 3; Phosphorylcholine; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazines; RNA Interference; Trans-Activators	2008
Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade. Cancer biology & therapy, 2011, Jul-15, Volume: 12, Issue:2 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrazines	2011
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jun-01, Volume: 22, Issue:11 Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multienzyme Complexes; Neoplasms; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Statistics, Nonparametric	2004
Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clinical prostate cancer, 2004, Volume: 3, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Maximum Tolerated Dose; Middle Aged; Prostatic Neoplasms; Pyrazines; Taxoids	2004
Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Feb-15, Volume: 13, Issue:4 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgens; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Docetaxel; Dose-Response Relationship, Drug; Humans; Interleukin-6; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrazines; Taxoids	2007
Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial. Clinical genitourinary cancer, 2007, Volume: 5, Issue:4 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Boronic Acids; Bortezomib; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Neoplasms; Pyrazines; Taxoids; Treatment Outcome	2007
A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer. The Journal of urology, 2007, Volume: 178, Issue:6 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrazines; Risk Assessment; Survival Rate; Treatment Outcome	2007
Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer. Investigational new drugs, 1998, Volume: 16, Issue:2 Topics: Aged; Androgens; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Prostatic Neoplasms; Pyrazines; Survival Rate	1998
CI-980 in advanced melanoma and hormone refractory prostate cancer. Investigational new drugs, 2000, Volume: 18, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carbamates; Drug Resistance, Neoplasm; Female; Humans; Male; Melanoma; Middle Aged; Prostatic Neoplasms; Pyrazines; Pyridines	2000

Other Studies

54 other study(ies) available for pyrazines and Cancer of Prostate

Article	Year
Tetramethylpyrazine reduces prostate cancer malignancy through inactivation of the DPP10‑AS1/CBP/FOXM1 signaling pathway. International journal of oncology, 2020, Volume: 57, Issue:1 Topics: Adult; Aged; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biopsy; Cell Line, Tumor; Cell Survival; CREB-Binding Protein; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Mice; Middle Aged; Prostate; Prostatic Neoplasms; Pyrazines; RNA, Long Noncoding; Signal Transduction; Up-Regulation; Xenograft Model Antitumor Assays	2020
A case report of combined treatment of gilteritinib and LH-RH agonist for Fms-related tyrosine kinase 3 receptor mutation-positive acute myeloid leukemia and bone marrow metastasis of prostate cancer. Annals of hematology, 2022, Volume: 101, Issue:2 Topics: Aniline Compounds; Bone Marrow Neoplasms; fms-Like Tyrosine Kinase 3; Gonadotropin-Releasing Hormone; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Oligopeptides; Prostatic Neoplasms; Pyrazines	2022
Tetramethylpyrazine inhibits prostate cancer progression by downregulation of forkhead box M1. Oncology reports, 2017, Volume: 38, Issue:2 Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasm Invasiveness; Prostatic Neoplasms; Pyrazines	2017
Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. Bioorganic & medicinal chemistry letters, 2013, Mar-15, Volume: 23, Issue:6 Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Half-Life; Humans; Male; Mice; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; TOR Serine-Threonine Kinases; Transplantation, Heterologous	2013
Antilipolytic drug boosts glucose metabolism in prostate cancer. Nuclear medicine and biology, 2013, Volume: 40, Issue:4 Topics: Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Fluorodeoxyglucose F18; Glucose; Humans; Hypolipidemic Agents; Male; Mice; Mice, Nude; Positron-Emission Tomography; Prostatic Neoplasms; Pyrazines; Tissue Distribution	2013
Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells: the role of IKKα. Journal of immunology (Baltimore, Md. : 1950), 2013, Sep-01, Volume: 191, Issue:5 Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Chromatin Immunoprecipitation; Enzyme-Linked Immunosorbent Assay; Humans; I-kappa B Kinase; Interleukin-8; Male; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Real-Time Polymerase Chain Reaction; RNA, Small Interfering; Transfection	2013
Induction of steroid sulfatase expression in PC-3 human prostate cancer cells by insulin-like growth factor II. Toxicology letters, 2013, Nov-25, Volume: 223, Issue:2 Topics: 17-Hydroxysteroid Dehydrogenases; Androstadienes; Boronic Acids; Bortezomib; Cell Line, Tumor; Chromones; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Humans; Insulin-Like Growth Factor II; Leupeptins; Male; Morpholines; NF-kappa B; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Polymerase Chain Reaction; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazines; Sequence Analysis, DNA; Signal Transduction; Steryl-Sulfatase; Sulfones; Sulfotransferases; Wortmannin	2013
Enhancing proteasome-lnhibitor effect by functionalized gold nanoparticles. Journal of biomedical nanotechnology, 2014, Volume: 10, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Gold; Humans; Male; Metal Nanoparticles; Prostatic Neoplasms; Proteasome Inhibitors; Pyrazines; Treatment Outcome	2014
[Bortezomib enhances the sensitivity of prostate cancer cells to natural killer cell-mediated cytotoxicity]. Zhonghua nan ke xue = National journal of andrology, 2014, Volume: 20, Issue:3 Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cytotoxicity, Immunologic; Humans; Killer Cells, Natural; Male; Prostatic Neoplasms; Pyrazines	2014
Apoptotic effects of proteasome and histone deacetylase inhibitors in prostate cancer cell lines. Genetics and molecular research : GMR, 2014, May-09, Volume: 13, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; NF-kappa B; Prostatic Neoplasms; Pyrazines	2014
Bortezomib prevents oncogenesis and bone metastasis of prostate cancer by inhibiting WWP1, Smurf1 and Smurf2. International journal of oncology, 2014, Volume: 45, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Prostatic Neoplasms; Pyrazines; Ubiquitin-Protein Ligases	2014
FOXP3-miR-146-NF-κB Axis and Therapy for Precancerous Lesions in Prostate. Cancer research, 2015, Apr-15, Volume: 75, Issue:8 Topics: Animals; Boronic Acids; Bortezomib; Cell Transformation, Neoplastic; Cells, Cultured; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Transgenic; MicroRNAs; Precancerous Conditions; Prostate; Prostatic Neoplasms; Pyrazines; Signal Transduction; Xenograft Model Antitumor Assays	2015
Ligustrazine Suppresses the Growth of HRPC Cells through the Inhibition of Cap- Dependent Translation Via Both the mTOR and the MEK/ERK Pathways. Anti-cancer agents in medicinal chemistry, 2015, Volume: 15, Issue:6 Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Eukaryotic Initiation Factor-4E; Humans; Male; MAP Kinase Signaling System; Phosphorylation; Prostatic Neoplasms; Protein Biosynthesis; Pyrazines; Signal Transduction; TOR Serine-Threonine Kinases	2015
Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. Journal of medicinal chemistry, 2015, Jul-09, Volume: 58, Issue:13 Topics: Animals; Antineoplastic Agents; Drug Discovery; Humans; Male; Models, Molecular; Molecular Structure; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrazines; Rats; Signal Transduction; Structure-Activity Relationship; TOR Serine-Threonine Kinases; Tumor Cells, Cultured	2015
SOX9 drives WNT pathway activation in prostate cancer. The Journal of clinical investigation, 2016, 05-02, Volume: 126, Issue:5 Topics: Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Mice, SCID; Neoplasm Proteins; Prostatic Neoplasms; Pyrazines; Pyridines; SOX9 Transcription Factor; Transcription Factor 4; Transcription Factors; Wnt Signaling Pathway; Xenograft Model Antitumor Assays	2016
Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation. World journal of urology, 2008, Volume: 26, Issue:5 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Docetaxel; Down-Regulation; Humans; Male; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Radiation-Sensitizing Agents; Taxoids; Tumor Cells, Cultured	2008
Velcade sensitizes prostate cancer cells to TRAIL induced apoptosis and suppresses tumor growth in vivo. Cancer biology & therapy, 2009, Volume: 8, Issue:1 Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Humans; In Situ Nick-End Labeling; Male; Mice; Prostatic Neoplasms; Pyrazines; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand	2009
Combination therapy with TRAIL: Recent developments and potential pitfalls. Cancer biology & therapy, 2009, Volume: 8, Issue:1 Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Drug Therapy, Combination; Humans; Male; Mice; Prostatic Neoplasms; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Transplantation, Heterologous	2009
Proteasome inhibitor bortezomib increases radiation sensitivity in androgen independent human prostate cancer cells. Urology, 2010, Volume: 75, Issue:4 Topics: Androgens; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Male; Prostatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Radiation-Sensitizing Agents; Tumor Cells, Cultured	2010
Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization. Cancer research, 2009, Nov-01, Volume: 69, Issue:21 Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cisplatin; Humans; Lactones; Leupeptins; Male; Melanoma; Membrane Potential, Mitochondrial; NF-kappa B; Phosphatidylethanolamine Binding Protein; Prostatic Neoplasms; Proteasome Inhibitors; Proto-Oncogene Proteins c-raf; Pyrazines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Snail Family Transcription Factors; TNF-Related Apoptosis-Inducing Ligand; Transcription Factors; Transfection; Tumor Cells, Cultured	2009
Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells. Oncogene, 2010, Jan-21, Volume: 29, Issue:3 Topics: Animals; Autophagy; Autophagy-Related Protein 5; Autophagy-Related Protein 7; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Cell Survival; Humans; Immunoblotting; Lactones; Lysosomes; Male; Microscopy, Electron, Transmission; Microtubule-Associated Proteins; Phagosomes; Prostatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Ubiquitin-Activating Enzymes	2010
NBRI16716A, a new antitumor compound against human prostate cancer cells, produced by Perisporiopsis melioloides Mer-f16716. The Journal of antibiotics, 2010, Volume: 63, Issue:6 Topics: Animals; Antibiotics, Antineoplastic; Ascomycota; Cell Line, Tumor; Female; Humans; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Inbred ICR; Mice, Nude; Neoplasms, Experimental; Prostatic Neoplasms; Pyrazines	2010
Pharmacological and functional properties of TRPM8 channels in prostate tumor cells. Pflugers Archiv : European journal of physiology, 2011, Volume: 461, Issue:1 Topics: Arginine; Calcium; Cell Line; Cell Line, Tumor; Cell Membrane; Clotrimazole; Cold Temperature; Endoplasmic Reticulum; Glycine; Humans; Male; Menthol; Prostate; Prostatic Neoplasms; Pyrazines; Pyridines; Pyrimidinones; TRPM Cation Channels	2011
Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model. Cancer science, 2011, Volume: 102, Issue:4 Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Docetaxel; Enzyme-Linked Immunosorbent Assay; Humans; Interleukin-6; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazines; RNA, Small Interfering; Taxoids; Tumor Cells, Cultured	2011
Development of a brain metastatic canine prostate cancer cell line. The Prostate, 2011, Volume: 71, Issue:12 Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Brain Neoplasms; Carcinogenicity Tests; Carcinoma; Cell Division; Cell Line, Tumor; Dogs; Immunohistochemistry; Incidence; Injections, Subcutaneous; Keratin-18; Keratin-7; Keratin-8; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Connective Tissue; Parathyroid Hormone-Related Protein; Phenylbutyrates; Prostatic Neoplasms; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Spinal Cord Neoplasms; Subcutaneous Tissue; Transplantation, Heterologous	2011
Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea. Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:5 Topics: Animals; Antineoplastic Agents; Ascorbic Acid; Boronic Acids; Bortezomib; Catechin; Chromatography, Liquid; Drug Screening Assays, Antitumor; Female; Humans; Male; Mice; Mice, SCID; Prostatic Neoplasms; Pyrazines; Tandem Mass Spectrometry; Tea; Xenograft Model Antitumor Assays	2011
Modulation of the tumor cell death pathway by androgen receptor in response to cytotoxic stimuli. Journal of cellular physiology, 2011, Volume: 226, Issue:11 Topics: Anilides; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cisplatin; Humans; Male; Nitriles; Prostatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Receptors, Androgen; Tosyl Compounds	2011
Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. Journal of molecular medicine (Berlin, Germany), 2012, Volume: 90, Issue:1 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Nucleus; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mitogen-Activated Protein Kinases; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; TOR Serine-Threonine Kinases; Transcription, Genetic	2012
Radioresistance of prostate cancer cells with low proteasome activity. The Prostate, 2012, Jun-01, Volume: 72, Issue:8 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Humans; Male; Mice; Mice, Nude; Phenotype; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Radiation Tolerance; Radiotherapy; Treatment Failure	2012
Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality. Cell cycle (Georgetown, Tex.), 2012, Jan-15, Volume: 11, Issue:2 Topics: Acetates; Adult; Aged; Aged, 80 and over; Androgen Receptor Antagonists; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Stability; Pyrazines; Receptors, Androgen; Receptors, Glucocorticoid; Transcription Factor CHOP; Transcriptional Activation; Tyramine	2012
Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells. International journal of urology : official journal of the Japanese Urological Association, 2012, Volume: 19, Issue:6 Topics: Antineoplastic Agents; Apoptosis; bcl-Associated Death Protein; Bombesin; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Endothelin-1; Humans; Interleukin-8; Male; Mitogen-Activated Protein Kinases; NF-kappa B; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; RNA, Messenger; Signal Transduction; Translocation, Genetic; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A	2012
Diltiazem enhances the apoptotic effects of proteasome inhibitors to induce prostate cancer cell death. The Journal of pharmacology and experimental therapeutics, 2012, Volume: 341, Issue:3 Topics: Acetylcysteine; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Calcium; Calcium Channel Blockers; Clinical Trials as Topic; Diltiazem; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Humans; Male; Prostatic Neoplasms; Protease Inhibitors; Pyrazines; Transfection; Tumor Cells, Cultured	2012
Why is management of cancer pain still a problem? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jun-01, Volume: 30, Issue:16 Topics: Analgesics; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Colorectal Neoplasms; Female; Healthcare Disparities; Humans; Lung Neoplasms; Male; Multiple Myeloma; Pain Management; Practice Patterns, Physicians'; Prostatic Neoplasms; Pyrazines	2012
Plasmablastic haemato-lymphoid neoplasm with a complex genetic signature of Burkitt lymphoma responding to bortezomib. Hematological oncology, 2013, Volume: 31, Issue:3 Topics: Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Burkitt Lymphoma; Fatal Outcome; Genes, myc; Herpesvirus 4, Human; Humans; Immunoglobulin M; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasms, Second Primary; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrazines; Retroperitoneal Neoplasms; Transcriptome; Translocation, Genetic	2013
Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity. Asian journal of andrology, 2012, Volume: 14, Issue:5 Topics: Antineoplastic Agents; Base Sequence; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytotoxicity, Immunologic; DNA Primers; Flow Cytometry; Histocompatibility Antigens Class I; Humans; Killer Cells, Natural; Male; Prostatic Neoplasms; Pyrazines; Real-Time Polymerase Chain Reaction	2012
Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells. The Journal of urology, 2012, Volume: 188, Issue:6 Topics: Animals; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Humans; Hydroxamic Acids; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Prostatic Neoplasms; Pyrazines; Random Allocation; RNA, Small Interfering; Sensitivity and Specificity; Ubiquitinated Proteins; Vorinostat; Xenograft Model Antitumor Assays	2012
Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Oct-01, Volume: 9, Issue:12 Topics: Androgens; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Cell Survival; Cysteine Endopeptidases; Drug Interactions; Electrophoretic Mobility Shift Assay; Humans; Luciferases; Male; Membrane Glycoproteins; Multienzyme Complexes; NF-kappa B; Prostatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha	2003
Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Molecular cancer therapeutics, 2003, Volume: 2, Issue:9 Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cysteine Endopeptidases; Endothelium, Vascular; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Multienzyme Complexes; Neoplasm Transplantation; Neovascularization, Pathologic; Prostatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A	2003
The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer research, 2003, Nov-01, Volume: 63, Issue:21 Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA, Neoplasm; Etoposide; Humans; Male; Nuclear Proteins; Oncogene Proteins, Viral; Papillomaviridae; Peptide Hydrolases; Phosphorylation; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Pyrazines; Subcellular Fractions; Transcriptional Activation; Transfection; Tumor Suppressor Protein p53	2003
Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells. Cancer science, 2004, Volume: 95, Issue:3 Topics: Androgens; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Division; Cell Line; Down-Regulation; Humans; In Situ Nick-End Labeling; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrazines; Receptors, Androgen	2004
Prostate intraepithelial neoplasia in Noble rats, a potential intermediate endpoint for chemoprevention studies. European journal of cancer (Oxford, England : 1990), 2004, Volume: 40, Issue:9 Topics: Animals; Antineoplastic Agents; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Eflornithine; Estradiol; Male; Models, Animal; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Pyrazines; Rats; Rats, Inbred Strains; Testosterone; Thiones; Thiophenes; Time Factors	2004
The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Molecular cancer therapeutics, 2005, Volume: 4, Issue:3 Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Western; Boronic Acids; Bortezomib; Carrier Proteins; Cell Line; Cell Line, Tumor; Cell Survival; Cells, Cultured; Colonic Neoplasms; Dose-Response Relationship, Drug; Down-Regulation; Fibroblasts; Green Fluorescent Proteins; Humans; Immunoprecipitation; Male; Membrane Glycoproteins; Membrane Proteins; Mice; Mitochondrial Proteins; Peptide Fragments; Plasmids; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA Interference; TNF-Related Apoptosis-Inducing Ligand; Transfection; Tumor Necrosis Factor-alpha	2005
Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer chemotherapy and pharmacology, 2005, Volume: 56, Issue:1 Topics: Boronic Acids; Bortezomib; Breast Neoplasms; Cyclin D1; Female; Gene Expression Regulation, Neoplastic; Humans; Male; NF-kappa B; Pancreatic Neoplasms; Prostatic Neoplasms; Protease Inhibitors; Pyrazines; Signal Transduction; Transcription, Genetic; Tumor Cells, Cultured	2005
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. Journal of medicinal chemistry, 2005, Apr-21, Volume: 48, Issue:8 Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androstadienes; Animals; Antineoplastic Agents; Azoles; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Humans; Isoenzymes; Male; Mice; Mice, SCID; Mutation; Prostatic Neoplasms; Pyrazines; Radioligand Assay; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship; Tissue Distribution; Transcription, Genetic; Transcriptional Activation; Xenograft Model Antitumor Assays	2005
Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer research, 2005, Jun-01, Volume: 65, Issue:11 Topics: Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Caspases; Cell Cycle Proteins; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Male; Membrane Glycoproteins; Prostatic Neoplasms; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Urinary Bladder Neoplasms	2005
[Proteasome inhibitors]. La Revue de medecine interne, 2005, Volume: 26, Issue:10 Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Docetaxel; Drug Therapy, Combination; Female; Graft vs Host Reaction; Humans; Kidney Neoplasms; Lung Neoplasms; Lymphoma, Mantle-Cell; Male; Mice; Multiple Myeloma; Prostatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Taxoids; Time Factors; Treatment Outcome; Tumor Cells, Cultured	2005
Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases. Prostate cancer and prostatic diseases, 2005, Volume: 8, Issue:4 Topics: Animals; Bone Neoplasms; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Disease Progression; Humans; Male; Mice; Mice, SCID; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Xenograft Model Antitumor Assays	2005
A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study). Contemporary clinical trials, 2006, Volume: 27, Issue:5 Topics: Aged; Anxiety; Depression; Follow-Up Studies; Humans; Hydrazines; Male; Middle Aged; Patient Satisfaction; Patient Selection; Prostatic Neoplasms; Pyrazines; Quinolines; Randomized Controlled Trials as Topic; Socioeconomic Factors	2006
An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib. Clinical oncology (Royal College of Radiologists (Great Britain)), 2006, Volume: 18, Issue:5 Topics: Aged; Boronic Acids; Bortezomib; Electrodiagnosis; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Nervous System Diseases; Prostatic Neoplasms; Protease Inhibitors; Pyrazines	2006
[Molecular-targeted therapy for hormone-refractory prostate cancer]. Hinyokika kiyo. Acta urologica Japonica, 2006, Volume: 52, Issue:6 Topics: Angiotensin Receptor Antagonists; Antineoplastic Agents; Atrasentan; Benzamides; Boronic Acids; Bortezomib; Calcitriol; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelin A Receptor Antagonists; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sulfonamides; Thalidomide; Vitamin D	2006
Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells. Molecular cancer therapeutics, 2006, Volume: 5, Issue:8 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; CDC2 Protein Kinase; Cell Division; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Humans; Male; Prostatic Neoplasms; Pyrazines; Taxoids; Tumor Cells, Cultured	2006
Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors. Cancer research, 2007, Feb-15, Volume: 67, Issue:4 Topics: Antigens, Neoplasm; Antineoplastic Agents; Boronic Acids; Bortezomib; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Squamous Cell; Caspase 3; Cell Hypoxia; Cell Line, Tumor; Cell Nucleus; Colonic Neoplasms; E1A-Associated p300 Protein; Enzyme Activation; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leupeptins; Male; Prostatic Neoplasms; Protease Inhibitors; Protein Binding; Pyrazines; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2007
Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis. The Prostate, 2008, Feb-01, Volume: 68, Issue:2 Topics: Apoptosis; Boronic Acids; Bortezomib; Caspase 8; Cell Line, Tumor; Cell Survival; Cells, Cultured; Epithelial Cells; Fas Ligand Protein; Half-Life; Humans; Male; Prostate; Prostatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Receptors, Death Domain; TNF-Related Apoptosis-Inducing Ligand	2008
Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:9 Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Carcinoma; Caspase Inhibitors; Caspases; Cell Adhesion; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Resistance, Neoplasm; Female; Humans; Male; Ovarian Neoplasms; Phosphorylation; Prostatic Neoplasms; Protease Inhibitors; Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Spheroids, Cellular; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein	2000